VIEWPOINTS


Viewpoints are a collection of news and opinion articles that capture key research developments and important issues in the field of oncology.


Do Patients with Locally Advanced Rectal Cancer Benefit from Adjuvant Chemotherapy?

Do Patients with Locally Advanced Rectal Cancer Benefit from Adjuvant Chemotherapy?

A recent letter in JCO discusses whether patients with locally advanced rectal cancer need adjuvant chemotherapy.

Next-Generation Sequencing Panels Cost-Effective for Diagnosis of Hereditary Colorectal Cancer

Next-Generation Sequencing Panels Cost-Effective for Diagnosis of Hereditary Colorectal Cancer

A decision model finds that the higher cost of new sequencing methods is justified by their clinical benefits.

Vitamin D Levels and Risk for Pancreatic Cancer

Vitamin D Levels and Risk for Pancreatic Cancer

Recent reports indicate a potential association between sunlight exposure and risk of pancreatic cancer.

New Genetic Sequencing May Lead to Urine Test for Bladder Cancer

New Genetic Sequencing May Lead to Urine Test for Bladder Cancer

Early research indicates the possibility for a urine test for bladder cancer.

Will Patient-Reported Outcomes Be Included in Oncology Product Labeling?

Will Patient-Reported Outcomes Be Included in Oncology Product Labeling?

FDA, industry, and patients are talking, but agreement on how to include patient experiences in oncology product prescribing information remains elusive.

Bipolar Androgen Therapy Showing Promise for Castration Resistant Prostate Cancer

Bipolar Androgen Therapy Showing Promise for Castration Resistant Prostate Cancer

Bipolar androgen therapy (BAT) may benefit some men with asymptomatic CRPC who have a low to moderate metastatic burden.

Alternate Sunitinib Schedules May Benefit Some with Metastatic Renal Cell Carcinoma

Alternate Sunitinib Schedules May Benefit Some with Metastatic Renal Cell Carcinoma

Understanding optimal dosing regimens for renal cell carcinoma (RCC) could lead to improvements in dosing for all oral anticancer therapies.

Anti-PD-L1 Antibody Demonstrates Antitumor Activity in Triple-Negative Breast Cancer

Anti-PD-L1 Antibody Demonstrates Antitumor Activity in Triple-Negative Breast Cancer

Report from a phase 1 trial presented at the 2015 American Association for Cancer Research (AACR) annual meeting.

Sunitinib Showing Promise for Small-Cell Lung Cancer

Sunitinib Showing Promise for Small-Cell Lung Cancer

A phase II trial shows promise for patients with extensive small cell lung cancer who currently have limited treatment options.

After Breast Cancer, Many Women Express Desire for Genetic Testing

After Breast Cancer, Many Women Express Desire for Genetic Testing

A survey of ethnically diverse women treated for breast cancer has identified a "complete failure" among health care professionals to address concerns about genetic risk.

Adjuvant Ipilimumab Improves Recurrence-Free Survival of High-Risk Stage 3 Melanoma

Adjuvant Ipilimumab Improves Recurrence-Free Survival of High-Risk Stage 3 Melanoma

In patients with completely resected high-risk stage 3 melanoma, adjuvant ipilimumab significantly improved recurrence-free survival.

Too Many Axillary Lymph Node Evaluations for Ductal Carcinoma in Situ, Researchers Report

Too Many Axillary Lymph Node Evaluations for Ductal Carcinoma in Situ, Researchers Report

Too many patients are undergoing axillary lymph node evaluation with breast-conserving surgery (BCS) for ductal carcinoma in situ (DCIS).

Myth: Oncology Patients Demand Inappropriate Interventions

Myth: Oncology Patients Demand Inappropriate Interventions

According to a JAMA study, only 8.7% of patients with cancer requested medical interventions and only 11.4% of those were deemed inappropriate.

Early Radiation Postprostatectomy May Not Affect Erectile Function

Early Radiation Postprostatectomy May Not Affect Erectile Function

Research indicates the addition of the time from prostatectomy to radiation therapy was not significant for adverse events.

Cardiovascular Risk in Men with Prostate Cancer on GnRH Agonist Therapy

Cardiovascular Risk in Men with Prostate Cancer on GnRH Agonist Therapy

Study of prostate cancer patients finds that treatment with GnRH agonists, but not antiandrogens, increases risk of cardiovascular events and mortality.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs